Literature DB >> 33315352

Demographic and clinical characteristics of children with autosomal dominant polycystic kidney disease: a single center experience

Belde Kasap Demir1,2, Fatma Mutlubaş2, Eren Soyaltın2, Caner Alparslan2, Merve Arya2, Demet Alaygut2, Seçil Arslansoyu Çamlar2, Afig Berdeli3, Önder Yavaşcan2.   

Abstract

Background/aim: In children with autosomal dominant polycystic kidney disease (ADPKD), clinical manifestations range from severe neonatal presentation to renal cysts found by chance. We aimed to evaluate demographic, clinical, laboratory findings, and genetic analysis of children with ADPKD. Materials and methods: We evaluated children diagnosed with ADPKD between January 2006 and January 2019. The diagnosis was established by family history, ultrasound findings, and/or genetic analysis. The demographic, clinical, and laboratory findings were evaluated retrospectively. Patients <10 years and ≥10 years at the time of diagnosis were divided into 2 groups and parameters were compared between the groups.
Results: There were 41 children (M/F: 18/23) diagnosed with ADPKD. The mean age at diagnosis was 7.2 ± 5.1 (0.6–16.9) years and the follow-up duration was 59.34 ± 40.56 (8–198) months. Five patients (12%) were diagnosed as very early onset ADPKD. All patients had a positive family history. Genetic analysis was performed in 29 patients (PKD1 mutations in 21, PKD2 mutations in 1, no mutation in 3). Cysts were bilateral in 35 (85%) of the patients. Only one patient had hepatic cysts. No valvular defect was defined in 12 patients detected. Only 1 patient had hypertension. None of them had chronic kidney disease. No difference could be demonstrated in sex, laterality of the cysts, maximum cyst diameter, cyst or kidney enlargement, follow-up duration, or GFR at last visit between Groups 1 and 2.
Conclusion: The majority of children with ADPKD had preserved renal functions and slight cyst enlargement during their follow-up. However, they may have different renal problems deserving closed follow-up. This work is licensed under a Creative Commons Attribution 4.0 International License.

Entities:  

Keywords:  Autosomal dominant polycystic kidney disease; children

Mesh:

Substances:

Year:  2021        PMID: 33315352      PMCID: PMC8203125          DOI: 10.3906/sag-2009-79

Source DB:  PubMed          Journal:  Turk J Med Sci        ISSN: 1300-0144            Impact factor:   0.973


  19 in total

Review 1.  A systematic review of glomerular hyperfiltration assessment and definition in the medical literature.

Authors:  Francois Cachat; Christophe Combescure; Michel Cauderay; Eric Girardin; Hassib Chehade
Journal:  Clin J Am Soc Nephrol       Date:  2015-01-07       Impact factor: 8.237

Review 2.  Autosomal dominant polycystic kidney disease.

Authors:  P A Gabow
Journal:  N Engl J Med       Date:  1993-07-29       Impact factor: 91.245

3.  Prospective change in renal volume and function in children with ADPKD.

Authors:  Melissa A Cadnapaphornchai; Kim McFann; John D Strain; Amirali Masoumi; Robert W Schrier
Journal:  Clin J Am Soc Nephrol       Date:  2009-04       Impact factor: 8.237

Review 4.  Hypertension in autosomal dominant polycystic kidney disease: a meta-analysis.

Authors:  Matko Marlais; Oliver Cuthell; Dean Langan; Jan Dudley; Manish D Sinha; Paul J D Winyard
Journal:  Arch Dis Child       Date:  2016-06-10       Impact factor: 3.791

5.  Presence of de novo mutations in autosomal dominant polycystic kidney disease patients without family history.

Authors:  Berenice Reed; Kim McFann; William J Kimberling; York Pei; Patricia A Gabow; Karen Christopher; Eric Petersen; Catherine Kelleher; Pamela R Fain; Ann Johnson; Robert W Schrier
Journal:  Am J Kidney Dis       Date:  2008-07-21       Impact factor: 8.860

Review 6.  Is Autosomal Dominant Polycystic Kidney Disease Becoming a Pediatric Disorder?

Authors:  Stéphanie De Rechter; Luc Breysem; Djalila Mekahli
Journal:  Front Pediatr       Date:  2017-12-20       Impact factor: 3.418

7.  Tolvaptan treatment for severe neonatal autosomal-dominant polycystic kidney disease.

Authors:  Rodney D Gilbert; Hazel Evans; Kazeem Olalekan; Arvind Nagra; Mushfequr R Haq; Mark Griffiths
Journal:  Pediatr Nephrol       Date:  2017-02-13       Impact factor: 3.714

Review 8.  Unmet needs and challenges for follow-up and treatment of autosomal dominant polycystic kidney disease: the paediatric perspective.

Authors:  Stéphanie De Rechter; Bert Bammens; Franz Schaefer; Max C Liebau; Djalila Mekahli
Journal:  Clin Kidney J       Date:  2018-12-17

9.  Clinical practice guideline monitoring children and young people with, or at risk of developing autosomal dominant polycystic kidney disease (ADPKD).

Authors:  Jan Dudley; Paul Winyard; Matko Marlais; Oliver Cuthell; Tess Harris; Jiehan Chong; John Sayer; Daniel P Gale; Lucy Moore; Kay Turner; Sarah Burrows; Richard Sandford
Journal:  BMC Nephrol       Date:  2019-04-30       Impact factor: 2.388

10.  Tolvaptan use in children and adolescents with autosomal dominant polycystic kidney disease: rationale and design of a two-part, randomized, double-blind, placebo-controlled trial.

Authors:  Franz Schaefer; Djalila Mekahli; Francesco Emma; Rodney D Gilbert; Detlef Bockenhauer; Melissa A Cadnapaphornchai; Lily Shi; Ann Dandurand; Kimberly Sikes; Susan E Shoaf
Journal:  Eur J Pediatr       Date:  2019-05-03       Impact factor: 3.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.